MK-3475, Merck

Drug: MK-3475 (pembrolizumab)
Company: Merck & Co.
Phase: Filed
Class: Anti-programmed death-1 (PD-1) MAb
2020 sales: $4.06 billion
Net present value: $16.7 billion

Don't count out Merck ($MRK), though. When Roger Perlmutter came in as the new R&D chief, he was forced to set in motion a major R&D restructuring to account for the lengthy dry spell at the well for new approvals. MK-3475, now dubbed pembrolizumab, changed the narrative back to the company's research potential. After executing a slow series of pratfalls on largely second-tier drugs, R&D is now betting heavily that its top contender can deliver a years-long feast of new revenues. This is a drug with major partnering potential, as a whole slate of combo studies now on the drawing board attest to. As a result of their success, the R&D budget is now expected to climb in the second half of this year. 

For more:
Merck takes to Europe with its promising PD-1 cancer drug
Merck steps up with more positive data on immuno-oncology star pembrolizumab
Merck's hot immuno-oncology prospect MK-3475 grabs clear lead in blockbuster race


Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.